ATG-101

DRUG2 trials

Sponsors

Antengene Biologics Limited, Antengene (Hangzhou) Biologics Co., Ltd.

Conditions

Advanced Solid TumorMature B-cell Non-Hodgkin LymphomaMetastatic Solid Tumor

Phase 1

A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

TerminatedNCT04986865

Antengene Biologics LimitedAdvanced Solid Tumor, Mature B-cell Non-Hodgkin Lymphoma, Metastatic Solid Tumor

Start: 2021-12-15End: 2025-01-31Updated: 2025-06-09

A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

TerminatedNCT05490043

Antengene (Hangzhou) Biologics Co., Ltd.Advanced Solid Tumor, Mature B-cell Non-Hodgkin Lymphoma, Metastatic Solid Tumor

Start: 2022-01-30End: 2025-03-17Updated: 2025-08-29

Related Papers

A first-in-human phase I study of ATG-031, anti-CD24 antibody, in patients with advanced solid tumors or B-cell non-Hodgkin lymphomas (PERFORM).

Journal of Clinical Oncology2024-06-014 citations